These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

865 related articles for article (PubMed ID: 25649148)

  • 1. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
    Cheshire P; Ayton S; Bertram KL; Ling H; Li A; McLean C; Halliday GM; O'Sullivan SS; Revesz T; Finkelstein DI; Storey E; Williams DR
    Mov Disord; 2015 May; 30(6):796-804. PubMed ID: 25649148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.
    Kish SJ; Tong J; Hornykiewicz O; Rajput A; Chang LJ; Guttman M; Furukawa Y
    Brain; 2008 Jan; 131(Pt 1):120-31. PubMed ID: 17956909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias.
    Roussakis AA; Politis M; Towey D; Piccini P
    Neurology; 2016 Mar; 86(12):1152-8. PubMed ID: 26920358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.
    Politis M; Wu K; Loane C; Brooks DJ; Kiferle L; Turkheimer FE; Bain P; Molloy S; Piccini P
    J Clin Invest; 2014 Mar; 124(3):1340-9. PubMed ID: 24531549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
    de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
    Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease.
    Vinuela A; Hallett PJ; Reske-Nielsen C; Patterson M; Sotnikova TD; Caron MG; Gainetdinov RR; Isacson O
    Brain; 2008 Dec; 131(Pt 12):3361-79. PubMed ID: 18988638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia.
    Sellnow RC; Newman JH; Chambers N; West AR; Steece-Collier K; Sandoval IM; Benskey MJ; Bishop C; Manfredsson FP
    Acta Neuropathol Commun; 2019 Jan; 7(1):8. PubMed ID: 30646956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
    Morissette M; Morin N; Grégoire L; Rajput A; Rajput AH; Di Paolo T
    Biochem Pharmacol; 2016 Jun; 109():62-69. PubMed ID: 27038656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compensatory neuritogenesis of serotonergic afferents within the striatum of a transgenic rat model of Parkinson's disease.
    Stemick J; Gauer C; Wihan J; Moceri S; Xiang W; von Hörsten S; Kohl Z; Winkler J
    Brain Res; 2020 Dec; 1748():147119. PubMed ID: 32919983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.
    Ciesielska A; Samaranch L; San Sebastian W; Dickson DW; Goldman S; Forsayeth J; Bankiewicz KS
    PLoS One; 2017; 12(2):e0169965. PubMed ID: 28166239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonergic Regulation of Synaptic Dopamine Levels Mitigates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
    Chen YH; Kuo TT; Wang V; Cheng PW; Huang EY; Ma KH; Greig NH; Olson L; Hoffer BJ; Tseng KY
    J Parkinsons Dis; 2024; 14(5):941-964. PubMed ID: 38905058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study.
    Smith R; Wu K; Hart T; Loane C; Brooks DJ; Björklund A; Odin P; Piccini P; Politis M
    Neurobiol Aging; 2015 Apr; 36(4):1736-1742. PubMed ID: 25649022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased excitability in serotonin neurons in the dorsal raphe nucleus in the 6-OHDA mouse model of Parkinson's disease.
    Prinz A; Selesnew LM; Liss B; Roeper J; Carlsson T
    Exp Neurol; 2013 Oct; 248():236-45. PubMed ID: 23810738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies.
    Sharma S; Singh S; Sharma V; Singh VP; Deshmukh R
    Biomed Pharmacother; 2015 Mar; 70():283-93. PubMed ID: 25776513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias.
    Calon F; Birdi S; Rajput AH; Hornykiewicz O; Bédard PJ; Di Paolo T
    J Neuropathol Exp Neurol; 2002 Feb; 61(2):186-96. PubMed ID: 11853020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
    Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
    J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.